BioTuesdays
Fate Therapeutics

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

Daxor

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

electroCore Logo

electroCore names Daniel Goldberger as CEO

Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...

Concert Pharma

Stifel cuts Concert Pharma to hold; PT to $8 from $18

Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...